Clinical Trial Search

Primary: Percentage of Participants With an Serum Bactericidal Assay (SBA) Using Human Complement (SBA-HC) Titer Greater or Than Equal to (≥) 1:8 and ≥1:4: Groups 1, 2, 3, 4, 6…

Primary: Proportions of Participants With Treatment-related Adverse Events — 22 Participants

Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml

Primary: Number of Participants Reporting Solicited Injection-Site and Systemic Reaction Following Vaccination With Either MenACYW Conjugate Vaccine or NIMENRIX® — 28; 31; 0; 1…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Through the End of the Up-titration Period…

Primary: Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) — 48; 42; 46; 7 Participants

Primary: Maximum Tolerated Dose (MTD) — 4; 4 Participants

Primary: Detection of Metastases — 7; 8; 2; 0 Participants

Primary: Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48 — -7.49; -0.18 kg — p=<0.001

Primary: Change From Baseline in Intraocular Pressure (IOP) at Week 8 — -4.68; -3.68; -4.56; -3.62 mm Hg

Primary: Stage 1: Percentage of Participants With Local Reactions Within 14 Days After Vaccination — 2.9; 12.5; 2.9; 6.3 percentage of participants

Primary: Alcohol Consumption — 71.8; 66.5; 11.4; 22.6 percentage of days heavy drinking

Primary: Donepezil Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Complete Response Rate Achieved 1 Month After Concurrent Chemotherapy and Radiation Treatment — 52 Participants — p=< 0.01

Primary: Response Rate R-HCVAD vs. R-CHOP — 40; 7; 2; 1 Participants